Literature DB >> 11403416

In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors.

M J Wright1, L M Wightman, C Lilley, M de Alwis, S L Hart, A Miller, R S Coffin, A Thrasher, D S Latchman, M S Marber.   

Abstract

The purpose was to determine the relative efficiency, toxicity and duration of expression following gene delivery by intramyocardial injection of naked DNA, naked DNA complexed to cationic liposomes, naked DNA complexed to cationic liposomes with integrin-targetting peptide, recombinant (E1-/E3-) adenovirus, recombinant adeno-associated virus and recombinant (ICP27-) herpes simplex virus. All vectors incorporated a LacZ reporter driven by a promoter containing the hCMV-IE promoter/enhancer. Efficiency was scored by counting positive cells in five standard microscopic sections harvested from the left ventricular apex. Rabbit hearts (n = 100) were examined from 2 to 56 days after injection. Uncomplexed and complexed naked DNA were very inefficient with less than one positive cell visible per heart. The viral vectors all resulted in robust gene expression with adenovirus being the most efficient by at least one order of magnitude before 21 days. However, despite disparate titres, the efficiency beyond 21 days of adenovirus and adeno-associated virus were comparable. In contrast to adeno-associated virus, both adenovirus and herpes-simplex virus were associated with a marked inflammatory response. Despite reporter gene activity appearing only after 21 days, adeno-associated virus shows comparative promise as a myocardial gene delivery vector.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403416     DOI: 10.1007/s003950170053

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  15 in total

Review 1.  Update on gene therapy for myocardial ischaemia and left ventricular systolic dysfunction or heart failure.

Authors:  Jerome Roncalli; Jörn Tongers; Douglas W Losordo
Journal:  Arch Cardiovasc Dis       Date:  2010-06-23       Impact factor: 2.340

Review 2.  Angiomyogenesis for myocardial repair.

Authors:  Husnain Kh Haider; Syed Ali Akbar; Muhammad Ashraf
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

3.  Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart.

Authors:  Carmela Zincarelli; Stephen Soltys; Giuseppe Rengo; Walter J Koch; Joseph E Rabinowitz
Journal:  Clin Transl Sci       Date:  2010-06       Impact factor: 4.689

Review 4.  Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure.

Authors:  Larissa Lipskaia; Elie R Chemaly; Lahouaria Hadri; Anne-Marie Lompre; Roger J Hajjar
Journal:  Expert Opin Biol Ther       Date:  2010-01       Impact factor: 4.388

5.  Targeted high-efficiency, homogeneous myocardial gene transfer.

Authors:  Tetsuo Sasano; Kan Kikuchi; Amy D McDonald; Shenghan Lai; J Kevin Donahue
Journal:  J Mol Cell Cardiol       Date:  2007-02-14       Impact factor: 5.000

6.  Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat.

Authors:  Lawrence T Bish; Kevin Morine; Meg M Sleeper; Julio Sanmiguel; Di Wu; Guangping Gao; James M Wilson; H Lee Sweeney
Journal:  Hum Gene Ther       Date:  2008-12       Impact factor: 5.695

Review 7.  Human studies of angiogenic gene therapy.

Authors:  Rajesh Gupta; Jörn Tongers; Douglas W Losordo
Journal:  Circ Res       Date:  2009-10-09       Impact factor: 17.367

8.  Noninvasive imaging of hypoxia-inducible factor-1α gene therapy for myocardial ischemia.

Authors:  Ian Y Chen; Olivier Gheysens; Zongjin Li; Julia A Rasooly; Qian Wang; Ramasamy Paulmurugan; Jarrett Rosenberg; Martin Rodriguez-Porcel; Juergen K Willmann; David S Wang; Christopher H Contag; Robert C Robbins; Joseph C Wu; Sanjiv S Gambhir
Journal:  Hum Gene Ther Methods       Date:  2013-10       Impact factor: 2.396

Review 9.  Gene and cell therapy for heart failure.

Authors:  Ebo D de Muinck
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

10.  The Use of Gene Therapy for Ablation of Atrial Fibrillation.

Authors:  Zhao Liu; J Kevin Donahue
Journal:  Arrhythm Electrophysiol Rev       Date:  2014-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.